FDA refines strategy with one-day inspectional assessment pilot
Initiative shown to enhance agency’s efficacy by increasing the number of facilities it can assess, without comprising regulatory rigour.
The US Food and Drug Administration (FDA) is piloting one-day inspectional assessments to improve efficiency and narrow the focus of inspectional resources.
The initiative is not designed to replace the agency’s standard inspections, but instead act as a supportive tool in its overall strategy. It also helps the FDA to develop more robust risk models. Additionally, shorter, focused screening assessments will complement standard FDA inspections.
The move may help buffer the strain resulting from major staffing restructuring under President Trump’s current term, which includes Prasad’s exit as CBER Director last month.
Data gathered from these assessments, eg, recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations, aiding enhanced targeting of future oversight activities,
So far, the pilot has proven
Already a member? Sign-in
